- Home
- VVPR vs MAIA Comparison
VVPR vs MAIA Comparison
Compare VVPR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVPR
- MAIA
- Stock Information
- Founded
- VVPR 2014
- MAIA 2018
- Country
- VVPR United Kingdom
- MAIA United States
- Employees
- VVPR N/A
- MAIA N/A
- Industry
- VVPR Power Generation
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- VVPR Utilities
- MAIA Health Care
- Exchange
- VVPR Nasdaq
- MAIA Nasdaq
- Market Cap
- VVPR 64.0M
- MAIA 56.3M
- IPO Year
- VVPR 2016
- MAIA 2022
- Fundamental
- Price
- VVPR $4.97
- MAIA $1.59
- Analyst Decision
- VVPR
- MAIA
- Analyst Count
- VVPR 0
- MAIA 0
- Target Price
- VVPR N/A
- MAIA N/A
- AVG Volume (30 Days)
- VVPR 1.4M
- MAIA 375.5K
- Earning Date
- VVPR 01-01-0001
- MAIA 08-11-2025
- Dividend Yield
- VVPR N/A
- MAIA N/A
- EPS Growth
- VVPR N/A
- MAIA N/A
- EPS
- VVPR N/A
- MAIA N/A
- Revenue
- VVPR $79,000.00
- MAIA N/A
- Revenue This Year
- VVPR N/A
- MAIA N/A
- Revenue Next Year
- VVPR N/A
- MAIA N/A
- P/E Ratio
- VVPR N/A
- MAIA N/A
- Revenue Growth
- VVPR N/A
- MAIA N/A
- 52 Week Low
- VVPR $0.62
- MAIA $1.40
- 52 Week High
- VVPR $8.88
- MAIA $3.74
- Technical
- Relative Strength Index (RSI)
- VVPR 46.76
- MAIA 50.99
- Support Level
- VVPR $4.40
- MAIA $1.46
- Resistance Level
- VVPR $6.28
- MAIA $1.65
- Average True Range (ATR)
- VVPR 0.50
- MAIA 0.09
- MACD
- VVPR -0.12
- MAIA 0.01
- Stochastic Oscillator
- VVPR 30.32
- MAIA 43.10
About VVPR VivoPower International PLC
Vivopower International PLC is a solar power company. It provides energy infrastructure generation, and distribution solutions and is also engaged in the development, construction, and sale of photovoltaic(PV) solar projects. Its operating segments include Solar Development, Critical Power Services, Sustainable Energy Solutions, Electric Vehicles, and Corporate Office. The majority of the firm's revenue is generated from the Electric Vehicles segment. Geographically its key revenue derives from the Netherlands.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.